Health-Related Quality of Life With Carboplatin-Paclitaxel or nab-Paclitaxel With or Without Pembrolizumab in Patients With Metastatic Squamous Non-Small-Cell Lung Cancer

Basit Öğe Kaydı
dc.authoridCicin, Irfan/0000-0002-7584-3868
dc.authoridPineda, Benjamin/0000-0002-1455-312X
dc.authoridPiperdi, Bilal/0000-0002-1315-3175
dc.authoridKopp, Hans-Georg/0000-0002-0825-8888
dc.authoridKowalski, Dariusz/0000-0002-9452-3229
dc.authorwosidliang, liang/IAO-8518-2023
dc.authorwosidli, xiao/HJP-5134-2023
dc.authorwosidnovello, silvia/K-6335-2016
dc.authorwosidli, xiaofeng/GXF-9442-2022
dc.authorwosidCicin, Irfan/AAQ-5575-2020
dc.authorwosidGumus, Mahmut/HTO-4176-2023
dc.authorwosidli, xiao/GSN-6181-2022
dc.contributor.authorMazieres, Julien
dc.contributor.authorKowalski, Dariusz
dc.contributor.authorLuft, Alexander
dc.contributor.authorVicente, David
dc.contributor.authorTafreshi, Ali
dc.contributor.authorGumus, Mahmut
dc.contributor.authorLaktionov, Konstantin
dc.date.accessioned2024-06-12T11:20:02Z
dc.date.available2024-06-12T11:20:02Z
dc.date.issued2020
dc.departmentTrakya Üniversitesien_US
dc.description.abstractPURPOSE In the phase 3 KEYNOTE-407 study, the addition of pembrolizumab to carboplatin-paclitaxel/ nab-paclitaxel significantly improved overall survival, progression-free survival, and objective response rate in patients with previously untreated metastatic squamous non-small-cell lung cancer (NSCLC), with little impact on severe toxicity. We present patient-reported outcomes (PROs) from KEYNOTE-407. METHODS Patients were randomly assigned to receive 4 cycles of pembrolizumab 200 mg or placebo once every 3 weeks plus carboplatin plus paclitaxel or nab-paclitaxel, followed by pembrolizumab or placebo for an additional 31 cycles. Health-related quality of life (HRQoL) was evaluated using the European Organisation for Research and Treatment of Cancer Treatment of Cancer Quality of Life Questionnaire-Core 30 (QLQ-C30) and Quality of Life Questionnaire-Lung Cancer Module 13 (QLQ-LC13). Key PRO endpoints were change from baseline to weeks 9 and 18 (during and after platinum therapy) in the QLQ-C30 global health status/quality of life (GHS/QoL) score and time to deterioration in the composite endpoint of cough, chest pain, or dyspnea from the QLQ-C30 and QLQ-LC13. Two-sided, nominal P values are provided. RESULTS A total of 554 and 553 patients completed >= 1 QLQ-C30 or >= 1 QLQ-LC13 assessment, respectively. GHS/QoL score improved for the pembrolizumab-combination group (least squares [LS] mean [95% CI] change from baseline: week 9, 1.8 [-0.9 to 4.4]; week 18, 4.3 [1.7 to 6.9]) and deteriorated in the placebo-combination group (week 9, -1.8 [-4.4 to 0.7]; week 18, -0.57 [-3.3 to 2.2]). Between-group differences were improved for the pembrolizumab-combination group (difference in LS mean scores: week 9, 3.6 [95% CI, 0.3 to 6.9], nominal P =.0337; week 18, 4.9 [1.4 to 8.3], nominal P=.0060). Median time to deterioration in cough, chest pain, or dyspnea was not reached in either group (hazard ratio, 0.79; 95% CI, 0.58 to 1.06]; nominal P=.125). CONCLUSION Addition of pembrolizumab to chemotherapy maintained or improved HRQoL measurements relative to baseline and improved HRQoL versus chemotherapy alone at weeks 9 and 18. These results support use of pembrolizumab plus chemotherapy as first-line therapy for metastatic squamous NSCLC. (c) 2019 by American Society of Clinical Oncologyen_US
dc.description.sponsorshipMerck Sharp & Dohme, a subsidiary of Merck & Co., Inc., Kenilworth, NJen_US
dc.description.sponsorshipSupported by Merck Sharp & Dohme, a subsidiary of Merck & Co., Inc., Kenilworth, NJen_US
dc.identifier.doi10.1200/JCO.19.01348
dc.identifier.endpage+en_US
dc.identifier.issn0732-183X
dc.identifier.issn1527-7755
dc.identifier.issue3en_US
dc.identifier.pmid31751163en_US
dc.identifier.scopus2-s2.0-85077943456en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.startpage271en_US
dc.identifier.urihttps://doi.org/10.1200/JCO.19.01348
dc.identifier.urihttps://hdl.handle.net/20.500.14551/25442
dc.identifier.volume38en_US
dc.identifier.wosWOS:000508197300011en_US
dc.identifier.wosqualityQ1en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherAmer Soc Clinical Oncologyen_US
dc.relation.ispartofJournal Of Clinical Oncologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectSymptom Burdenen_US
dc.subjectChemotherapyen_US
dc.subjectQlq-C30en_US
dc.titleHealth-Related Quality of Life With Carboplatin-Paclitaxel or nab-Paclitaxel With or Without Pembrolizumab in Patients With Metastatic Squamous Non-Small-Cell Lung Canceren_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu